


: Phase 3 Study Design¹

Randomized, Double-Blind, Event-Driven Outcomes Study in Patients with ATTR-CM



^aRandomization was stratified according to the use of tafamidis at baseline (yes versus no), ATTR disease type (hATTR or wtATTR), and NYHA class and age at baseline (NYHA class I or II and age <75 years versus all others). ATTR, transthyretin amyloidosis; ATTR-CM, transthyretin amyloidosis with cardiomyopathy; CV, cardiovascular; DB, double-blind; hATTR, hereditary transthyretin amyloidosis; HF, heart failure; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire Overall Summary; NYHA, New York Heart Association; OLE, open-label extension; PND, polyneuropathy disability; Q6M, every 6 months; SC, subcutaneous; TTR, transthyretin; wtATTR, wild-type transthyretin amyloidosis. 1. Fontana et al. Heart Failure 2025, May 17–20, 2025, Belgrade, Serbia. Poster. 2. Alnylam Pharmaceuticals, Inc. 2026. <https://investors.alnylam.com/press-release?id=29796> (Accessed June 2, 2026).